Business News • PR NewsWire • Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

PARIS and BOSTON, Aug. 2, 2021 /PRNewswire/ -- Servier, a global pharmaceutical company, today announced the global Phase 3 double blinded placebo controlled AGILE study of TIBSOVO (ivosidenib tablets) in combination with the chemotherapy azacitidine in adults with previously untreated...

View More : https://www.prnewswire.com:443/news-releases/servier-announces-positive-topline-data-from-the-global-phase-3-study-of-ti...

Releted News by prnewswire

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Medallia, Inc. - MDLA

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Retail Properties of America, Inc. - RPAI

TriRx Completes Acquisition of Elanco Animal Health Facility in Shawnee, Kansas

Servier annonce des résultats positifs de l'étude internationale de phase 3 sur TIBSOVO® (comprimés d'ivosidénib) en association avec l'azacitidine chez des patients atteints de leucémie myéloïde aiguë non traitée auparavant et porteurs d'une mutation IDH1